Zhang H, Chen QF, Lip GYH, Tilg H, Valenti L, Somers VK, et al. Burden of metabolic diseases, 1990–2023, with forecasts to 2030 for the Asia-Pacific region. Metabolism. 2026. https://doi.org/10.1016/j.metabol.2026.156575.

Article  PubMed  Google Scholar 

Verde L, Barrea L, Bowman-Busato J, Yumuk VD, Colao A, Muscogiuri G. Obesogenic environments as major determinants of a disease: it is time to re-shape our cities. Diabetes Metab Res Rev. 2024;40(1):e3748. https://doi.org/10.1002/dmrr.3748.

Article  CAS  PubMed  Google Scholar 

Lonardo A, Zheng MH, Weiskirchen R. Food insecurity is an emerging risk factor for liver disease: a scoping review. Expert Rev Gastroenterol Hepatol. 2025;19(9):1033–49. https://doi.org/10.1080/17474124.2025.2545812.

Article  CAS  PubMed  Google Scholar 

Lonardo A, Weiskirchen R. Liver and obesity: a narrative review. Explor Med. 2025;6:1001334. https://doi.org/10.37349/emed.2025.1001334.

Article  CAS  Google Scholar 

Lugari S, Baldelli E, Lonardo A. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms. Metab Target Organ Damage. 2023;3:5. https://doi.org/10.20517/mtod.2022.38.

Article  CAS  Google Scholar 

Wu C, Targher G, Byrne CD, Mao Y, Cheung TT, Yilmaz Y, et al. Global, regional, and national burden of primary liver cancer attributable to metabolic risks: an analysis of the Global Burden of Disease Study 1990–2021. Am J Gastroenterol. 2025;120(10):2280–90. https://doi.org/10.14309/ajg.0000000000003288.

Article  PubMed  Google Scholar 

Zheng S, Chan SW, Liu F, Liu J, Chow PKH, Toh HC, et al. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges. Cancers (Basel). 2024;16(8):1582. https://doi.org/10.3390/cancers16081582.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–79. https://doi.org/10.1586/17474124.2015.1028363.

Article  CAS  PubMed  Google Scholar 

Fouad Y, Yu ML, Hamid S, Gish RG, Eslam M. Hepatitis C elimination: is it time to redefine the goals? Nat Rev Gastroenterol Hepatol. 2026. https://doi.org/10.1038/s41575-026-01184-x. (Epub ahead of print).

Article  PubMed  Google Scholar 

Ma Y, Wang J, Xiao W, Fan X. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions. Front Med. 2024;11:1410668. https://doi.org/10.3389/fmed.2024.1410668.

Article  Google Scholar 

Lonardo A, Suzuki A. Sex differences in alcohol-related liver disease, viral hepatitis, metabolic dysfunction-associated steatotic liver disease, and hepatocellular carcinoma. Explor Dig Dis. 2025;4:1005101. https://doi.org/10.37349/edd.2025.1005101.

Article  CAS  Google Scholar 

Reiter FP, Geier A. TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma. Lancet. 2025;405(10474):174–6. https://doi.org/10.1016/S0140-6736(24)02680-1.

Article  CAS  PubMed  Google Scholar 

Koustas E, Trifylli EM, Sarantis P, Karamouzis MV. Innovative approaches to hepatocellular carcinoma: diagnostic breakthroughs, biomarker integration, and artificial intelligence. Biomedicines. 2025;13(10):2439. https://doi.org/10.3390/biomedicines13102439.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405(10492):1851–64. https://doi.org/10.1016/S0140-6736(25)00403-9.

Article  CAS  PubMed  Google Scholar 

Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835–47. https://doi.org/10.1016/S0140-6736(23)01796-8.

Article  CAS  PubMed  Google Scholar 

Xu J, Zhang Y, Wang G, Chen W, Li Z, Gu S, et al. SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: a randomized phase 3 trial. J Clin Oncol. 2024;42:4092. https://doi.org/10.1200/JCO.2024.42.16_suppl.4092.

Article  Google Scholar 

Ben Khaled N, Mörtl B, Beier D, Reiter FP, Pawlowska-Phelan D, Teufel A, et al. Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study. Eur J Cancer. 2023;192:113248. https://doi.org/10.1016/j.ejca.2023.113248.

Article  CAS  PubMed  Google Scholar 

Muthukutty P, Heo J, Yoo SY. Therapeutic strategies for hepatocellular carcinoma: current advances and future perspectives. Vaccines (Basel). 2026;14(2):189. https://doi.org/10.3390/vaccines14020189.

Article  PubMed  PubMed Central  Google Scholar 

Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025;83(4):899–908. https://doi.org/10.1016/j.jhep.2025.03.033.

Article  PubMed  Google Scholar 

Mauro E, de Castro T, Zeitlhoefler M, Sung MW, Villanueva A, Mazzaferro V, et al. Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep. 2025;7(12):101571. https://doi.org/10.1016/j.jhepr.2025.101571.

Article  PubMed  PubMed Central  Google Scholar 

Wonglhow J, Sathitruangsak C, Sunpaweravong P, Wetwittayakhlang P, Dechaphunkul A. Real-world systemic treatment patterns, survival outcomes, and prognostic factors in advanced hepatocellular carcinoma: a 15-year experience from a low-resource setting. Cancers (Basel). 2025;17(17):2729. https://doi.org/10.3390/cancers17172729.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–62. https://doi.org/10.1016/S0140-6736(22)01200-4.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. https://doi.org/10.1038/s41571-018-0073-4.

Article  PubMed  PubMed Central  Google Scholar 

Lonardo A, Jamalinia M, Zheng MH. How to identify MASLD forms secondary to endocrine derangements in clinical practice. Eur Med J. 2025. https://doi.org/10.33590/emjhepatol/QVCY8477.

Article  Google Scholar 

Mantovani A, Csermely A, Bilson J, Borella N, Enrico S, Pecoraro B, et al. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut. 2024;73(9):1554–61. https://doi.org/10.1136/gutjnl-2024-332491.

Article  CAS  PubMed  Google Scholar 

Yuan S, Ebrahimi F, Bergman D, Vujković M, Scorletti E, Ruan X, et al. Thyroid dysfunction in MASLD: results of a nationwide study. JHEP Rep. 2025;7(5):101369. https://doi.org/10.1016/j.jhepr.2025.101369.

Article  PubMed  PubMed Central  Google Scholar 

Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol. 2009;6(4):236–47. https://doi.org/10.1038/nrgastro.

Article  CAS  PubMed